Good day, 360!
Here are some of our top movers today.
And don’t miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text “RAGE” to 1-(888) 487-1534📲.
Be the best prepared trader on the Street!
FOCUS LIST🔎
NMHI – Up over 140% in the pre-market, after announcing $29.7 million financing yesterday
STEM – Up over 11% in pre after announcing it will support 484 MW Hungarian solar portfolio in company’s largest software deal in EMEA
RGNX – Up over 18% in pre after announcing exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases
Still Not in Bullseye Trades?
Then you missed Jeff’s Pick of the Week: DJT
Rockets, baby!
And learn WHY he’s trading WHAT he’s trading…
HOTLIST🔥
NMHI – Up over 140% in the pre-market, after announcing $29.7 million financing yesterday
Nature’s Miracle Holding Inc. (NMHI) is an agriculture technology company that provides lighting and grow media products to growers in the controlled environment agriculture industry in the United States and Canada.
In the pre-market yesterday, the company announcedthat it entered into a Securities Purchase Agreement (“SPA”) with a single institutional investor (“Investor”) on January 10, 2025. The SPA allows Nature’s Miracle, subject to customary conditions, to sell up to $29.7 million in the aggregate of a newly-designated class of convertible preferred stock to the Investor.
After closing down 38% yesterday on low volume, buyers have come in sending the stock trading over 140% higher in the pre-market.
The first target for bulls is the pre-market high at $3.39.
Above it, targets to the upside are $4, $5, $5.50, $6, $6.86.
Below $3.39, targets to the downside are $3, $2.80, $2.60, $2.46, $2.20, $2, $1.80, $1.47 and then a gap fill at $1.13.
STEM – Up over 11% in pre after announcing it will support 484 MW Hungarian solar portfolio in company’s largest software deal in EMEA
Stem, Inc. (STEM) operates as a digitally connected, intelligent, and renewable energy storage network provider worldwide.
In the pre-market this morning, the company announcedthat its award-winning solar monitoring and optimization solutions will be standard in supporting the commercial operation of a 484 megawatt (MW) solar portfolio for Neovolt, one of the largest asset owners in Hungary.
Under the five-year agreement, Stem’s PowerTrack Web will monitor, optimize, and control eight utility-scale sites in Hungary, through a comprehensive view across the entire portfolio.
Shares of STEM traded up over 11% in the pre-market in reaction to the news.
The $0.73 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.76, $0.80, $0.8315 and then the pre-market high at $0.8590. Beyond that, $0.92, $1, $1.13, $1.20, $1.35, $1.50 and then $1.68 come into play.
Below $0.73, targets to the downside are $0.70, $0.67 and then $0.57 with $0.50 below that.
*sponsored by 1440 Media
Looking for unbiased, fact-based news? Join 1440 today.
Upgrade your news intake with 1440! Dive into a daily newsletter trusted by millions for its comprehensive, 5-minute snapshot of the world’s happenings. We navigate through over 100 sources to bring you fact-based news on politics, business, and culture—minus the bias and absolutely free.
RGNX – Up over 18% in pre after announcing exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases
REGENXBIO Inc. (RGNX) is a clinical-stage biotechnology company that provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
In the pre-market this morning, the company announceda strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for Mucopolysaccharidosis I (MPS I), also known as Hurler syndrome.
Under the terms of the agreement, REGENXBIO will receive $110 million at closing and up to an additional $700 million if certain milestones are achieved, consisting of $40 million in potential development and regulatory milestones and $660 million in potential sales milestones. REGENXBIO will also receive meaningful double-digit royalties on net sales in the U.S. and Asia (collectively, the “Licensed Territory”).
RGNX had a market capitalization of $344.34million based on yesterday’s close according to Finviz.
Shares of RGNX are up over 18% in the pre-market in reaction to the news.
The $7.25 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $7.65, $8, $8.35, $8.60, $8.70, $8.80 and then the pre-market high at $8.93. Beyond that $9.30 and $10 come into play.
Below $7.25, targets to the downside are $7, $6.95 $6.80 and then $6.56.
MARKET NEWS 📰
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
